ArticleP & T : a peer-reviewed journal for formulary management2011

Sipuleucel-T (provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer.

Enock Anassi et al.PubMed ↗Full text ↗

No numbers read from the abstract.